145 related articles for article (PubMed ID: 28094847)
1. Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review.
Fisher SA; Lamikanra A; Dorée C; Gration B; Tsang P; Danby RD; Roberts DJ
Br J Haematol; 2017 Feb; 176(3):448-463. PubMed ID: 28094847
[TBL] [Abstract][Full Text] [Related]
2. High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT.
Danby RD; Zhang W; Medd P; Littlewood TJ; Peniket A; Rocha V; Roberts DJ
Bone Marrow Transplant; 2016 Jan; 51(1):110-8. PubMed ID: 26389831
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
Gu G; Yang JZ; Zhang JQ; Sun LX
Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
[TBL] [Abstract][Full Text] [Related]
6. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
[TBL] [Abstract][Full Text] [Related]
7. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
[TBL] [Abstract][Full Text] [Related]
8. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
9. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
10. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
[TBL] [Abstract][Full Text] [Related]
11. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
[TBL] [Abstract][Full Text] [Related]
12. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
Matsuoka K; Kim HT; McDonough S; Bascug G; Warshauer B; Koreth J; Cutler C; Ho VT; Alyea EP; Antin JH; Soiffer RJ; Ritz J
J Clin Invest; 2010 May; 120(5):1479-93. PubMed ID: 20389017
[TBL] [Abstract][Full Text] [Related]
13. The absolute number of regulatory T cells in unmanipulated peripheral blood grafts predicts the occurrence of acute graft-versus-host disease post haplo-identical hematopoietic stem cell transplantation.
Ding L; Zhu H; Yang Y; Yan HM; Zhang HH; Han DM; Wang ZD; Zheng XL; Liu J; Zhu L; Mei-Xue ; Guo ZK; Wang HX
Leuk Res; 2017 May; 56():13-20. PubMed ID: 28161606
[TBL] [Abstract][Full Text] [Related]
14. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
[TBL] [Abstract][Full Text] [Related]
16. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
19. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
20. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]